Enspryng™ (satralizumab-mwge)

New Genentech Data at 2021 AAN Highlight Impact and Breadth of Expanding Neuroscience Portfolio

Retrieved on: 
Thursday, April 8, 2021
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Clinical trials, Other Health, Brain disorders, Rare diseases, Monoclonal antibodies, Medical specialties, Branches of biology, Clinical medicine, Progressive multifocal leukoencephalopathy, Ocrelizumab, PML, Leukoencephalopathy, spinal muscular atrophy, Evrysdi™ (risdiplam), multiple sclerosis, Ocrevus, neuromyelitis optica spectrum disorder, Enspryng™ (satralizumab-mwge), Genentech in neuroscience, Genentech

If you get infusion reactions, your healthcare provider may need to stop or slow down the rate of your infusion.

Key Points: 
  • If you get infusion reactions, your healthcare provider may need to stop or slow down the rate of your infusion.
  • Progressive Multifocal Leukoencephalopathy (PML): Although no cases have been seen with Ocrevus treatment in clinical trials, PML may happen with Ocrevus.
  • Tell your healthcare provider right away if you have any new or worsening neurologic signs or symptoms.
  • These may include problems with thinking, balance, eyesight, weakness on 1 side of your body, strength, or using your arms or legs.

New Data Show Genentech’s Enspryng Significantly Reduces Severity and Risk of Relapse in Neuromyelitis Optica Spectrum Disorder

Retrieved on: 
Thursday, September 10, 2020
Health, Clinical trials, Research, Science, Pharmaceutical, Optical, Biotechnology, Autoimmune diseases, Organ systems, Integral membrane proteins, Medical specialties, Rare diseases, Health, Neuromyelitis optica, Orphan drugs, Monoclonal antibodies, Aquaporin 4, Satralizumab, NMO, SAkuraStar and SAkuraSky in NMOSD, neuromyelitis optica spectrum disorder (NMOSD), Enspryng™ (satralizumab-mwge), Genentech in neuroscience, Genentech

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), will present new Enspryng (satralizumab-mwge) data on reducing relapse severity in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare disease of the central nervous system.

Key Points: 
  • Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), will present new Enspryng (satralizumab-mwge) data on reducing relapse severity in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare disease of the central nervous system.
  • A relapse was categorized as severe if it resulted in a change of 2 points on the Expanded Disability Status Scale.
  • SAkuraStar is a Phase III multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Enspryng monotherapy administered to patients with neuromyelitis optica spectrum disorder (NMOSD).
  • Enspryng is a prescription medicine used to treat neuromyelitis optica spectrum disorder (NMOSD) in adults who are aquaporin-4 (AQP4) antibody positive.

Genentech to Present New Data in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder at MSVirtual2020

Retrieved on: 
Thursday, September 3, 2020
Women, Seniors, Clinical trials, Cardiology, Biotechnology, Pharmaceutical, Consumer, Health, Optical, Oncology, Medical specialties, Autoimmune diseases, Health, Clinical medicine, Monoclonal antibodies, Integral membrane proteins, Rare diseases, Orphan drugs, Neuromyelitis optica, Aquaporin 4, Aquaporin, Satralizumab, Ocrevus, Enspryng™ (satralizumab-mwge), Genentech in neuroscience, Genentech

If you get infusion reactions, your healthcare provider may need to stop or slow down the rate of your infusion.

Key Points: 
  • If you get infusion reactions, your healthcare provider may need to stop or slow down the rate of your infusion.
  • If you have an active infection, your healthcare provider should delay your treatment with Ocrevus until your infection is gone.
  • Tell your healthcare provider right away if you have any new or worsening neurologic signs or symptoms.
  • Enspryng is a prescription medicine used to treat neuromyelitis optica spectrum disorder (NMOSD) in adults who are aquaporin-4 (AQP4) antibody positive.

 FDA Approves Genentech’s Enspryng for Neuromyelitis Optica Spectrum Disorder

Retrieved on: 
Saturday, August 15, 2020
Medical Supplies, Health, FDA, Hospitals, Pharmaceutical, Optical, Biotechnology, Autoimmune diseases, Organ systems, Integral membrane proteins, Clinical medicine, Rare diseases, Monoclonal antibodies, Medical specialties, Neuromyelitis optica, Multiple sclerosis, Satralizumab, Aquaporin 4, Genentech, Medical Supplies, Health, FDA, Hospitals, Pharmaceutical, Optical, Biotechnology, Autoimmune diseases, Organ systems, Integral membrane proteins, Clinical medicine, Rare diseases, Monoclonal antibodies, Medical specialties, Neuromyelitis optica, Multiple sclerosis, Satralizumab, Aquaporin 4, Genentech, SAkuraStar and SAkuraSky in NMOSD, neuromyelitis optica spectrum disorder (NMOSD), Enspryng™ (satralizumab-mwge), Genentech in neuroscience, Genentech

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Enspryng (satralizumab-mwge) as the first and only subcutaneous treatment for adults living with anti-aquaporin-4 (AQP4) antibody positive neuromyelitis optica spectrum disorder (NMOSD).

Key Points: 
  • Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Enspryng (satralizumab-mwge) as the first and only subcutaneous treatment for adults living with anti-aquaporin-4 (AQP4) antibody positive neuromyelitis optica spectrum disorder (NMOSD).
  • After years of dedicated effort and collaboration, the FDA approval of Enspryng exemplifies how patients, industry, and academia can find solutions together.
  • Enspryng can be administered in the home by a person living with NMOSD or a caregiver following training from a healthcare provider.
  • Enspryng is a prescription medicine used to treat neuromyelitis optica spectrum disorder (NMOSD) in adults who are aquaporin-4 (AQP4) antibody positive.